Pure Bioscience Stock Cash And Equivalents
| PUREDelisted Stock | USD 0.09 0.03 26.83% |
Pure Bioscience fundamentals help investors to digest information that contributes to Pure Bioscience's financial success or failures. It also enables traders to predict the movement of Pure Pink Sheet. The fundamental analysis module provides a way to measure Pure Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pure Bioscience pink sheet.
Pure |
Pure Bioscience Company Cash And Equivalents Analysis
Pure Bioscience's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Pure Bioscience Cash And Equivalents | 511 K |
Most of Pure Bioscience's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pure Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Pure Bioscience has 511 K in Cash And Equivalents. This is 99.96% lower than that of the Household Products sector and 99.96% lower than that of the Consumer Staples industry. The cash and equivalents for all United States stocks is 99.98% higher than that of the company.
Pure Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pure Bioscience's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pure Bioscience could also be used in its relative valuation, which is a method of valuing Pure Bioscience by comparing valuation metrics of similar companies.Pure Bioscience is currently under evaluation in cash and equivalents category among its peers.
Pure Fundamentals
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (1.98) % | ||||
| Current Valuation | 13.51 M | ||||
| Shares Outstanding | 111.36 M | ||||
| Shares Owned By Insiders | 41.23 % | ||||
| Number Of Shares Shorted | 222.97 K | ||||
| Price To Earning | 12.49 X | ||||
| Price To Book | 3.85 X | ||||
| Price To Sales | 8.00 X | ||||
| Revenue | 1.85 M | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (3.27 M) | ||||
| Net Income | (3.49 M) | ||||
| Cash And Equivalents | 511 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 239 K | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 2.02 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (2.42 M) | ||||
| Short Ratio | 2.56 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 15 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 13.36 M | ||||
| Total Asset | 4.48 M | ||||
| Retained Earnings | (103.22 M) | ||||
| Working Capital | 3.61 M | ||||
| Current Asset | 6.14 M | ||||
| Current Liabilities | 2.54 M | ||||
| Z Score | 0.8 | ||||
| Net Asset | 4.48 M |
About Pure Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pure Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pure Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pure Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Pure Pink Sheet
If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |